• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

NovoCure Gaps Sharply Higher for a Breakout: How to Play It

Let's check out the charts and indicators of both NovoCure and Zai Lab.
By BRUCE KAMICH
Jan 05, 2023 | 11:26 AM EST
Stocks quotes in this article: NVCR, ZLAB

Shares of NovoCure ( NVCR) gapped sharply higher Thursday as traders reacted to news of NovoCure and Zai Lab ( ZLAB) announcing that a lung cancer therapy they are developing met its main goal in a late-stage trial.
 
Let's check out the charts and indicators of both NovoCure and Zai Lab.  

NovoCure

In the daily bar chart of NVCR, below, I can see a huge upside price gap with Thursday's price action. The shares have gapped above all the highs of 2022. Impressive. Prices have gapped above the 50-day and the 200-day moving average lines. The trading volume is heavy so far Thursday.
 
The On-Balance-Volume (OBV) line shows a rise from June telling me that buyers of NVCR have been more aggressive for several months leading up Thursday's gap. The Moving Average Convergence Divergence (MACD) looks like it will cross above the zero line today for an outright buy signal. 
 
 
In the weekly Japanese candlestick chart of NVCR, below, we don't have Thursday's price action plotted so we have to use our imagination. The shares are trading well above the trading range of the past year. Prices are above the bottoming 40-week moving average line.
 
The weekly OBV line has been in a downward trend from the middle of 2021. The MACD oscillator is just slightly below the zero line. 
 
 
 
In this daily Point and Figure chart of NVCR, below, we can see Thursday's rally with the gap filled in and a potential price target in the $188 area. 
 
 
 
In the weekly Point and Figure chart of NVCR, below, the software is still generating a downside price target. A trade at $91 or higher this Friday (a weekly chart) should turn the chart bullish. 
 
 

Zai Lab

Meanwhile, shares of Zai Lab ( ZLAB) also gapped higher Thursday but prices have not broken out over the highs of September. 
 
 
Bottom-line strategy: Investors seem pretty excited about this news but the question for me is where can I go long NVCR and what should I risk? As a technical analyst, I need to see more price action before making a recommendation. Prices could trade sideways or correct lower giving us an opportunity to go long with an appropriate stop loss order. Stay tuned.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Drug Approvals | Investing | Stocks | Technical Analysis | Healthcare | Life Sciences | Pharmaceuticals

More from Stocks

Traders Face the Fed Facts

James "Rev Shark" DePorre
Feb 8, 2023 4:26 PM EST

We've seen some denial about the level of Fed hawkishness, and the action now reflects a more realistic view of the economic situation.

Further Price Weakness Lies Ahead for Zoom Video

Bruce Kamich
Feb 8, 2023 2:35 PM EST

Here's what traders should avoid.

Here Are 2 Reasonably Valued Stocks Made for the 'Compression'

Bret Jensen
Feb 8, 2023 11:30 AM EST

These companies managed to produce solid results in a difficult fourth quarter.

Snap-On Is Close to a Major Upside Breakout

Bruce Kamich
Feb 8, 2023 11:18 AM EST

Here's what aggressive traders could do now.

'What Me Worry?' Market Is Ignoring Big-Time Wall Street Bears

James "Rev Shark" DePorre
Feb 8, 2023 11:17 AM EST

What is most notable about three of the most influential market strategists is how bearish they are.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:20 AM EST PETER TCHIR

    Powell, 0DTE Options and How I View This Market Right Now

    Fed Chair Powell is saying all the things I think ...
  • 08:22 AM EST REAL MONEY

    LIVE EVENT: Bruce Kamich and Todd Campbell Share Their Stock Market Insights

    This Monday, Feb. 6 at 12 p.m., our very own exper...
  • 02:58 PM EST REAL MONEY

    Sarge Guilfoyle Breaks Down the Jobs Report, Fed Policy and Stocks!

    Watch it here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login